Alessandra Cupri Selected Research

Therapeutics

9/2023	Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditions.
12/2022	Previous therapy with immune checkpoint inhibitor as a cause of hypothyroidism, myositis, and renal insufficiency in a candidate for allogeneic hematopoietic transplantation.
8/2012	Infliximab therapy in hematologic malignancies: handle with care.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alessandra Cupri Research Topics

Disease

5	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2022 - 06/2015
5	Multiple Myeloma 01/2020 - 01/2008
4	Infections 09/2023 - 12/2017
3	Non-Hodgkin Lymphoma (Lymphosarcoma) 09/2023 - 11/2020
3	Neoplasms (Cancer) 12/2022 - 01/2008
3	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 12/2017 - 05/2010
2	Hematologic Diseases (Blood Diseases) 09/2023 - 01/2023
2	Nausea 02/2022 - 11/2020
2	Vomiting 02/2022 - 11/2020
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 01/2008
2	Leukemia 01/2022 - 02/2013
2	Hematologic Neoplasms (Hematological Malignancy) 02/2013 - 08/2012
1	Breakthrough Infections 09/2023
1	COVID-19 09/2023
1	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 09/2023
1	Primary Myelofibrosis (Myelosclerosis) 01/2023
1	Leishmaniasis 01/2023
1	Renal Insufficiency (Renal Failure) 12/2022
1	Hypothyroidism 12/2022
1	Myositis (Idiopathic Inflammatory Myopathies) 12/2022
1	Pneumonia (Pneumonitis) 01/2022
1	Capillary Leak Syndrome 01/2022
1	Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive) 01/2022
1	Thrombotic Microangiopathies 01/2022
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2018
1	Lymphoma (Lymphomas) 01/2014
1	Genetic Translocation (Chromosomal Translocation) 05/2010

Drug/Important Bio-Agent (IBA)

3	plerixafor FDA Link 01/2020 - 01/2014
3	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2020 - 01/2014
2	Monoclonal AntibodiesIBA 09/2023 - 12/2022
2	CytokinesIBA 01/2023 - 01/2019
2	netupitantIBA 02/2022 - 11/2020
2	Palonosetron (Aloxi)FDA Link 02/2022 - 11/2020
2	Dexamethasone (Maxidex)FDA LinkGeneric 11/2020 - 01/2014
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2020 - 01/2014
2	Imatinib Mesylate (Gleevec)FDA Link 12/2017 - 02/2013
2	Tyrosine Kinase InhibitorsIBA 12/2017 - 05/2010
1	tixagevimabIBA 09/2023
1	cilgavimabIBA 09/2023
1	AntibodiesIBA 01/2023
1	ruxolitinibIBA 01/2023
1	Immune Checkpoint InhibitorsIBA 12/2022
1	fludarabineIBA 01/2022
1	Busulfan (Busulfex)FDA Link 01/2022
1	Thiotepa (Triethylenethiophosphoramide)FDA LinkGeneric 01/2022
1	Neurokinin-1 Receptor AntagonistsIBA 11/2020
1	AntiemeticsIBA 11/2020
1	Serotonin (5 Hydroxytryptamine)IBA 11/2020
1	Proteasome InhibitorsIBA 01/2019
1	Immunomodulating AgentsIBA 01/2019
1	ponatinibIBA 01/2018
1	Methylprednisolone FDA LinkGeneric 12/2017
1	SteroidsIBA 12/2017
1	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2014
1	Cisplatin (Platino)FDA LinkGeneric 01/2014
1	Proteins (Proteins, Gene)FDA Link 02/2013
1	Infliximab (Remicade)FDA Link 08/2012
1	Bortezomib (Velcade)FDA Link 01/2008

Therapy/Procedure

4	Drug Therapy (Chemotherapy) 12/2022 - 01/2018
4	Hematopoietic Stem Cell Transplantation 01/2022 - 01/2018
3	Therapeutics 09/2023 - 08/2012
2	Transplantation 12/2022 - 01/2021
2	Stem Cell Transplantation 02/2022 - 11/2020
1	Immunotherapy 12/2022
1	Bone Marrow Transplantation (Transplantation, Bone Marrow) 01/2018
1	Homologous Transplantation 06/2015
1	Aftercare (After-Treatment) 02/2013